• Abbisko Cayman unit Abbisko Therapeutics presented new model-based development work for ABSK-011 (irpagratinib) at the PAGE Meeting.
• Poster data outlined a joint tumor growth–progression-free survival modeling framework in advanced FGF19+ hepatocellular carcinoma.
• A separate poster compared Maspectra with NONMEM for ABSK-011 population pharmacokinetic modeling, highlighting use of China-developed software.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260604-12188379), on June 04, 2026, and is solely responsible for the information contained therein.